Quantitative Decision Making in Pharmaceutical Drug Development via
  Confidence Distributions by Johnson, Geoffrey S
ar
X
iv
:2
00
5.
04
72
1v
1 
 [s
tat
.A
P]
  1
0 M
ay
 20
20
Quantitative Decision Making in Pharmaceutical
Development via Confidence Distributions
Geoffrey S Johnson
GlaxoSmithKline
1250 S. Collegeville Rd, Collegeville, PA 19426, U.S.A.
Abstract
The Bayesian paradigm is often chosen for decision making in clinical development due to its prob-
abilistic statements around parameters. These probability statements are visually depicted through
prior and posterior distributions, “distribution estimates” of an unknown quantity of interest, and
are powerful tools for visualizing and pooling prior information and expert opinion with current data.
Under the frequentist paradigm the analogous distribution estimate is a confidence distribution, a
sample-dependent ex-post object supported on the parameter space that depicts all possible p-values
and confidence intervals one could construct given the observed data. Confidence distributions are a
powerful visual tool and allow for the inclusion of historical data and expert opinion via meta-analysis.
We demonstrate the use of hypothesis testing via confidence distributions when defining end-of-
study success and displaying study results, as well as in performing inference on power for progression
through all phases of pharmaceutical development. Desired inference on phase 3 power is used to
reverse engineer the hypothesis, significance level, and sample size required in phase 2. Extrapolation
between endpoints is also demonstrated, and a discussion is provided on multiple comparisons.
Keywords: Quantitative Decision Making, Pharmaceutical Clinical Development, Confidence Distribution,
Probability of Success, Assurance.
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1 Introduction
The need for quantitative decision making rules in the pharmaceutical industry across all phases of clinical
development is paramount.1–3 This entails Go/No-Go decisions from phase 1 through 3, and just as im-
portant is the probability of achieving these decisions. The Bayesian paradigm is often chosen for decision
making in clinical development due to its probabilistic statements around parameters. These probabil-
ity statements are visually depicted through prior and posterior distributions, “distribution estimates”
of an unknown quantity of interest, and are powerful tools for visualizing and pooling prior information
and expert opinion with current data. Spiegelhalter et al.4 illustrate this and highlight its application to
forming stopping rules for early efficacy, futility, and safety, as well as planning future studies. Under the
frequentist paradigm the analogous distribution estimate is a confidence distribution, a sample-dependent
ex-post object that depicts all possible p-values and confidence intervals one could construct given the
observed data for a parameter of interest.5,6 This distribution is supported on the parameter space and
has the look and feel of a Bayesian prior or posterior, but does not depict a random parameter. Instead,
the confidence distribution summarizes all possible inference one could perform based on a given data
set using a particular hypothesis test or confidence interval method. Confidence distributions allow for
meta-analysis7 and can be used to capture and incorporate expert opinion,8 providing a powerful visual
tool for decision making across all phases of clinical development.
The original idea for the confidence distribution dates back to Sir Ronald Fisher, who initially termed
it the fiducial or “faith” distribution. He viewed the p-value as a continuous measure of evidence drawing
inspiration from Jeffreys’s work in objective Bayesianism, and opposed the Neyman-Wald approach to
hypothesis testing. He also opposed the other end of statistical inference using personal or subjective
probabilities championed by Savage and de Finetti.9 Fisher developed likelihood based inference aiming
to combine information from different sources with an emphasis on model coherence and optimality, and
intended the fiducial distribution to be a universal approach for Bayesian-like inference in the absence
of a prior distribution. Text books and institutions ultimately adopted the Neyman-Wald approach to
hypothesis testing, obscuring the true merit of the p-value. However, in the decades since there has been
renewed interest in the topic using a purely frequentist interpretation, and the confidence distribution may
have become one of Fisher’s greatest achievements.9
Section 2 formally defines a confidence distribution, its link to hypothesis testing, and its usefulness in
performing a meta-analysis. It also shows the connection to Bayesian priors/posteriors and the sampling
distribution of the maximum likelihood estimator. Section 3 demonstrates the use of confidence distribu-
tions in the decision making framework across phases 2 and 3 of pharmaceutical development. Desired
inference on phase 3 power is used to reverse engineer the hypothesis, significance level, and sample size
required in phase 2. Extrapolation between endpoints is also demonstrated, and a discussion is provided
on why adjustment for multiple comparisons is not required if one adopts a Fisherian point of view. SAS
code is provided in Appendix I.
2 Confidence Distributions
2.1 From Confidence Intervals to Confidence Distributions
A confidence interval for a parameter θ is a set of plausible true values of θ, given the dataX = x observed.
Two well-known and often related methods for producing confidence intervals are inverting a family of
hypothesis tests, and using a pivotal quantity. The most familiar example of this is inverting the likelihood
ratio test. If a one-sided test is inverted for all values of θ in the parameter space, the resulting distribution
function depicts all possible p-values and confidence intervals given the data. That is, under H0 : θ = θ0
the likelihood ratio test statistic -2logλ(X, θ0) follows an asymptotic χ
2
1 distribution (See Appendix D).
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The one-sided p-value testing H0 : θ ≤ θ0,
H(θ) =


[
1− Fχ2
1
(
− 2logλ(x, θ)
)]
/2 if θ ≤ θˆ
[
1 + Fχ2
1
(
− 2logλ(x, θ)
)]
/2 if θ > θˆ,
(1)
as a function of θ is the corresponding cumulative confidence distribution function. The confidence density,
h(θ) = dH(θ)/dθ, is easily approximated in a data step over changes in θ. This recipe of viewing the p-value
as a function of θ given the data produces a confidence distribution for any hypothesis test. For instance,
when the sampling distribution of an estimator θˆ(X) is well approximated by a normal distribution a
confidence distribution for θ is easily produced by inverting a Wald test, H(θ) = 1 − Φ
(
[θˆ(x) − θ]/sˆe
)
.
Section 3.2.3 highlights the connection between a cumulative confidence distribution function and a power
curve. Appendices A and B provide the formal definition of a confidence interval10 and distribution,8 and
an example is discussed involving a discrete parameter space.
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(c) Confidence Distribution (Likelihood Ratio Test)
(b) Posterior (Normalized Likelihood)(a) Estimated Sampling Distribution
Figure 1: (a) Estimated sampling distribution for the MLE of an exponential data likelihood supported by θˆ
assuming θ = θˆmle=1.5 and n = 5. (b) Bayesian posterior from improper “dθ” prior (normalized likelihood)
supported by θ. (c) Confidence distribution based on the likelihood ratio test supported by θ.
The histogram in Figure 1, supported by θˆ(x), depicts the plug-in sampling distribution for the maxi-
mum likelihood estimator (MLE) of the mean for an exponential distribution data likelihood with n = 5
and θˆmle = 1.5. Assuming θ = θˆmle = 1.5, this is an estimate of the sampling behavior of the MLE for all
other replicated experiments, a Gamma(5,0.3) distribution. The normalized likelihood (proper Bayesian
posterior from improper “dθ” prior)11 depicted by the thin blue curve is a transformation of the plug-in
sampling distribution onto the parameter space, also a Gamma(5,0.3) distribution. The bold black curve in
Figure 1 is also data dependent and supported on the parameter space, but represents confidence intervals
of all levels from inverting the likelihood ratio test. It is a transformation of the sampling behavior of the
test statistic under the null onto the parameter space, a distribution of p-values. Each value of θ takes
its turn playing the role of null hypothesis and hypothesis testing (akin to “proof by contradiction”) is
used to infer the unknown fixed true θ. The area under this curve to the right of the reference line is the
p-value or significance level when testing the hypothesis H0 : θ ≥ 2.35. This probability forms the level
of confidence that θ is greater than or equal to 2.35. Similarly, the area to the left of the reference line is
the p-value when testing the hypothesis H0 : θ ≤ 2.35. One can also identify the two-sided equal-tailed
100(1 − α)% confidence interval by finding the complement of those values of θ in each tail with α/2
significance. Additional figures showing the construction of this confidence distribution are provided in
Appendix C.
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One interpretation of posterior probability is it measures one’s belief about the unknown fixed θ given
the observed data. Another interpretation is the unknown fixed true θ belongs to a known collection or
prevalence of θ’s (prior distribution) and the observed data is used to subset the collection of θ’s, forming
the posterior distribution. A third interpretation is that all values of θ are true simultaneously; the truth
exists in a superposition12 depending on the data observed. Ascribing any of these interpretations to the
posterior allows one to make probability statements about hypotheses given the data. While the p-value
is typically not interpreted in the same manner, it does show us the plausibility of a hypothesis given
the data. Singh et al.13 and others highlight an interesting coincidence that when a normalized likeli-
hood approaches a normal distribution (symmetric shift model) with increasing sample size, it is a valid
asymptotic confidence distribution. In some settings under comparable models Bayesian and frequentist
inference are asymptotically equivalent.5,8,11
One might notice the similarity between the confidence distribution and posterior distribution and
wonder under what circumstances is each one preferable. At its essence this is a matter of scientific
objectivity.11 To the Bayesian, probability is axiomatic and measures the experimenter. To the frequentist,
probability measures the experiment and must be verifiable. The Bayesian interpretation of probability
as a measure of belief is unfalsifiable. Only if there exists a real life mechanism by which we can sample
values of θ can a probability distribution for θ be verified. In such settings probability statements about
θ would have a purely frequentist interpretation (see the example in Appendix B). This may be a reason
why frequentist inference is ubiquitous in the scientific literature.
2.2 Confidence Distributions for Meta-Analysis
The Bayesian paradigm is often chosen for pooling prior information with current data, and has applications
in forming stopping rules for early efficacy, futility, and safety, as well as planning future studies. The
frequentist analogue is a fixed effect meta-analysis. For a normal model a fixed-effect meta analysis may
take the form
p(c) = Φ
(
1
σˆ1
Φ−1
(
p1
)
+ 1σˆ2Φ
−1
(
p2
)
(
1
σˆ2
1
+ 1
σˆ2
2
)1/2
)
, (2)
where p-values p1 and p2 are back-transformed into z-scores, inversely weighted by their estimated standard
errors, and transformed once again into a combined p-value. Viewing each p-value as a function of θ, this
same convolution formula can be applied to confidence distributions, i.e.
H(c)(θ) = Φ
(
1
σˆ1
Φ−1
(
H1(θ)
)
+ 1σˆ2Φ
−1
(
H2(θ)
)
(
1
σˆ2
1
+ 1
σˆ2
2
)1/2
)
. (3)
Even in non-normal settings this formula works well to preserve Fisher information.8 Depending on the
model and hypothesis test the standard errors above could be considered a function of θ under the null
hypothesis. Additionally, if the standard errors depend on any nuisance parameters, these nuisance pa-
rameters could be profiled to account for the uncertainty in their estimation.
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(f) Combined Confidence Distribution(e) Posterior Distribution
(d) Current Data Confidence Distribution(c) Current Data Normalized Likelihood
(b) Historical Confidence Distribution(a) Historical Prior Distribution
Figure 2: (a) Prior distribution based on historical data for binomial proportion, θˆHistBayes = 0.90, n = 50. (b)
Confidence distribution (likelihood ratio test) based on historical data for binomial proportion, θˆHistmle = 0.90, n = 50.
(c) Normalized binomial likelihood for current data, θˆCurrentBayes = 0.87, n = 30. (d) Confidence distribution (likelihood
ratio test) for current data, θˆCurrentmle = 0.87, n = 30. (e) Posterior distribution based on historical prior distribution
and current data likelihood. (f) Convolution of historical and current confidence distributions.
Figure 2 depicts a meta-analysis using confidence distributions for a binomial proportion θ. Density
(a) represents a prior distribution (normalized likelihood) based on historical data with an estimate of
0.90 and a sample size of n = 50. This same information is depicted in (b) as a confidence distribution
resulting from the likelihood ratio test. The normalized current data binomial likelihood is shown in curve
(c) based on an estimate of 0.87 resulting from n = 30. This same information can be represented as a
likelihood ratio confidence distribution, (d). Using Bayes theorem, curves (a) and (c) combine to form
(e). Using the convolution formula in Equation (3), (b) and (d) combine to form (f). Alternatively, one
could multiply the historical and current likelihoods together to form a joint likelihood, and use this to
perform the likelihood ratio test and construct the combined confidence distribution. This multiplication
of independent likelihoods is precisely what Bayes theorem accomplishes (plus normalization), without the
inversion of a hypothesis test. In more complicated situations involving nuisance parameters, Equations (2)
and (3) highlight the notion of division-of-labor11 allowing one to avoid construction of an all-encompassing
model.
3 Decision Making Across Pharmaceutical Development
3.1 Decision Rules for End-of-Study Success
Regardless of which paradigm one operates under, hypothesis testing is the very heart of quantitative
decision making in pharmaceutical development. Confidence distributions are a powerful visual for de-
picting the probability statements that define success, and the study results. The null value to be tested
in each phase depends not only on regulatory requirements, but also on what is clinically meaningful and
commercially viable. When showing a treatment effect over placebo or an active comparator, the null
value need not be zero, and the significance level need not be 0.05. The example below uses confidence
distributions to visualize the success criteria in a phase 2 and 3 clinical development plan.
Example: A phase 2 and 3 development plan is being created for an asset to treat an immuno-
inflammation disorder. Phase 3 is planned as a non-inferiority study versus an active control arm using a
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difference in proportions on a binary responder index. The non-inferiority margin is set by the regulatory
agency at -0.12, as is the significance level of 0.025. Phase 2 is a dose finding study on a continuous
endpoint. This study also collects data on the responder index and includes an active comparator arm
to estimate the difference in proportions planned for phase 3. A stricter non-inferiority margin of -0.05 is
considered in phase 2, but since the sample size in phase 2 is typically smaller than in phase 3, a larger
significance level of 0.20 is tolerated. Based on a literature review the estimated response proportion for
the active comparator is 0.43 with N=1200.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.
=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
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Figure 3: Phase 2 likelihood ra io test of H0 : θ ≤ −0. 5 with N=90 per arm at α=0.2. Phase 3 likelihood ratio
test of H0 : θ ≤ −0.12 with N=365 per arm at α=0.025.
Figure 3 uses confidence distributions resulting from a likelihood ratio test on the difference in pro-
portions to demonstrate what the minimum phase 2 and phase 3 success criteria look like. The left panel
is based on N=90 subjects per arm with an estimated response rate of 0.43 on the control arm, and an
estimated difference in proportions of 0.01 (minimum detectable effect). This results in a p-value just
under 0.20 when testing against the -0.05 non-inferiority margin, H0 : θ ≤ −0.05. That is, one must be
at least 80% confident that the true difference in proportions is greater than -0.05 in order to succeed in
phase 2. This is nearly equivalent to a test about the -0.12 non-inferiority margin at the 0.025 significance
level. The right panel is based on N=365 subjects per arm and an estimated difference in proportions of
-0.05. This results in a p-value just under 0.025 when testing H0 : θ ≤ −0.12, or equivalently, one must
be at least 97.5% confident that the true difference in proportions is greater than -0.12. The phase 2 null
hypothesis was chosen as the value at which phase 3 power is 50%. This will be seen more clearly in
Section 3.2.3.
The confidence distributions above showcase the p-value as a continuous measure of evidence when
performing inference on a parameter. While it is important to have a clear definition of technical success
before conducting a trial, Figure 3 makes it clear there is nothing materially different between a p-value
of 0.024 and 0.026, or 0.19 and 0.21 and so on. This allows for flexibility in decision making and reminds
us that no hypothesis is proven false with a single small p-value, nor is it proven true with a large one. All
we can do is provide the weight of the evidence. This resonates with the American Statistical Association
(ASA) statement on statistical significance and the p-value.14 It also reflects the original intentions of
Fisher’s statistical significance and inductive reasoning.15
Equally important as the end-of-study success rule is the power of achieving it. Both of these factor
into the Go/No-Go decision, and it is not enough to provide a point estimate of power. One must also
perform inference on power.
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3.2 Priors, Power, and Probability of Success
3.2.1 Prior Elicitation
Expert opinion can be used to perform inference on the power of a future study when no historical data
is available.16 Many times expert opinion is elicited through a ‘chips-in-bins’ activity to construct a dis-
tribution estimate of the true treatment effect.17 This of course is inadmissible as scientific evidence, but
allows the Bayesian to explore belief probabilities and allows the frequentist to explore inference based on
hypothetical experimental evidence. The available knowledge and information can be seen as virtual data,
and each expert considers all possible point estimates that data like this could give rise to, essentially
bootstrapping the sampling distribution of the estimator.8 These bootstrapped sampling distributions are
then averaged in some way to form a single distribution. If the experts were all bootstrapping from the
same information their distributions would be nearly indistinguishable, but this is rarely the case. The het-
erogeneity between the experts’ distributions suggests an extra layer of bootstrap sampling. Each expert’s
perspective represents a bootstrapped sample of the available information, from which they bootstrap
repeatedly to form their distribution. This explains the heterogeneity, and in theory the heterogeneity
should be ‘averaged out’ when these distributions are combined. The combined sampling distribution
itself may be considered an asymptotic confidence distribution, but can also be used to invert a hypothesis
test. See Figure 1 for the connection between a belief distribution and a sampling distribution.
Example continued : Six experts were assembled to elicit a distribution estimate for the difference in
proportions of the responder index in the target patient population. After a briefing on the literature to
date all six experts’ distributions were averaged to form a single distribution with a mean of -0.02. This was
used as the maximum likelihood point estimate for a likelihood ratio test of the difference in proportions
based on N=350 on the investigational product, a 0.43 response rate in the control arm with N=1200,
and inverted to form a confidence distribution. The virtual or effective sample size was determined by the
variance of the combined sampling distribution, the assumed data variance, and the literature review (see
Appendix E). Figure 4 shows the power curves for the success criteria outlined in Figure 3, the combined
power curve (product) for success in both phase 2 and phase 3, and the elicited confidence distribution for
the difference in proportions described above.
-0.2 -0.1 0.0 0.1 0.2
True Difference in Proportions
0.0
0.2
0.4
0.6
0.8
1.0
P
o
w
e
r
0
4
8
12
16
20
24
C
o
n
fi
d
e
n
c
e
 D
e
n
s
it
y
Confidence DensityPhase 2 and 3 Power
Phase 3 PowerPhase 2 Power
=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 4: Phase 2 power curve esting H0 : θ ≤ −0.05 with N=90 per arm at α=0.2. Phase 3 power curve testing
H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for θ based on historical data and expert
opinion.
7
3.2.2 Power and Probability of Success
A confidence distribution for θ can be used to obtain a confidence distribution for the power of a future
study, depicting all possible confidence intervals and p-values for hypotheses around power. Viewing power
as a function of theta, β(θ), its confidence density,
h(β) =
dH(θ)
dβ(θ)
, (4)
can be easily approximated in a data step over changes in θ, and hence changes in power, using h(β) ≈
∆H(θ)/∆β(θ). For ease of notation we are allowing the function h(·) to be defined by its argument
so that h(θ) is not the same function as h(β). Using the invariance property, βˆmle = β(θˆmle) is the
maximum likelihood estimate for power. Momentarily treating h(θ) as a probability distribution for θ, we
can calculate the Bayesian quantity probability of success, or assurance,
βˆpos =
∫
β(θ) · h(θ)dθ (5)
=
∫
β · h(β)dβ. (6)
One interpretation is h(θ) measures belief about θ for the treatment under investigation so that probabil-
ity of success is not an estimate of the long-run probability of achieving end-of-study success, it is simply
the belief about achieving end-of-study success. Probability of success is un-conditional on θ, but it is
conditional on the belief around θ. Another interpretation is the treatment under investigation, indexed
by an unknown θ, is one of many such treatments according to a known h(θ). Imagining an urn full
of treatments, each with a different efficacy, if we were to conduct the experiment an infinite number of
times with every treatment in the urn, probability of success is the proportion of times we would achieve
end-of-study success. Probability of success is un-conditional on θ, meaning it is not an estimate of the
long-run probability of success for the treatment under investigation. Rather, it pertains to all treatments
like it. A third interpretation is, since we cannot know the true θ it exists in a state of superposition12
where all values are true simultaneously according to h(θ). If we were to repeat the experiment an infinite
number of times without updating our inference on θ, probability of success is the proportion of times
we would achieve end-of-study success with the data following the corresponding predictive distribution.
Probability of success is again un-conditional on θ, though it is conditional on h(θ). A final interpretation,
there is a single true θ for the treatment under investigation and (5) is the average of all possible power
estimates over the coverage probability in h(θ). Despite the integration over θ, (5) is not unconditional on
θ. Equation (6) is a point estimate of power, which by definition is conditional on θ. Although consistent
as an estimator, it is biased towards 0.5 since θ is a fixed quantity. The uncertainty around βˆMLE and
βˆPoS is not ignored, it is displayed in the confidence distribution for power.
Probability of success is typically approximated through numerical integration by sampling from h(θ).
However, once the confidence distribution for power, h(β), is approximated as outlined above, probability
of success can be easily approximated using a Riemann sum
βˆpos ≈
∑
β · h(β)∆β∑
h(β)∆β
=
∑
β(θ) ·∆H(θ)∑
∆H(θ)
. (7)
This can be accomplished in a single data step and a call to Proc Means with a weight statement, and
computes in a fraction of a second. When considering phase 2 and phase 3 together, probabiliy of success
can be defined as
8
βˆpos2,3 =
∫
β3(θ)β2(θ) · h(θ) dθ, (8)
where β2 and β3 are phase 2 and phase 3 power respectively. This is easily approximated as in Equation
(7). Reading Equation (8) from left to right, for a given θ, β3(θ)β2(θ) is the power of succeeding in both
phase 2 and phase 3, averaged over what we currently infer about θ. In this quantity the truth does not
change from phase 2 to phase 3, and probability of success is based solely on what we infer now about θ.
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Figure 5: Solid lines depict resulting confidence distributions for power, h(β) = dH(θ)/dβ(θ), in phase 2, phase 3,
and overall. Dotted lines depict maximum likelihood estimates of power.
Figure 5 shows the resulting confidence distributions for power using Equation (4), and probability of
success calculations using (7) and (8) for the difference in proportions example. These figures suggest a
larger sample size in phase 2 would be warranted to increase the maximum likelihood and probability of
success estimates for power in phase 2 and overall. If 80% or 90% power is desired in the phase 3 study its
sample size would need to be increased as well. However, these statements ignore the coverage probability
in the confidence distributions.
9
N=45 N=65 N=85 N=115 N=155 N=205 N=275 N=365 N=465 N=600 N=765
Sample Size per Arm
0.2
0.4
0.6
0.8
1.0
P
h
a
s
e
 3
 P
o
w
e
r
Probability of Success EstimateMaximum Likelihood Estimate
foot
footFigure 6: Estimated phase 3 power when testing H0 : θ ≤ −0.12 at α=0.025 at various sample sizes with 80%
confidence limits based on the elicitation.
The bias of βˆPoS makes it a useful summary measure since a relatively high or low value indicates
the coverage probability is centered near high or low values of power, respectively, but this still does not
provide a complete picture. For instance, had the elicited confidence distribution been wider and shifted to
the right probability of success would increase at most sample sizes, but this produces U-shaped coverage
probability around power18 (see Appendix F). Of course the elicitation is merely opinion and should not
weigh too heavily on decision making. What matters more is inference based on real data. For this, one
will need to conduct the phase 2 study.
3.2.3 Conditioning on Phase 2 Success
If one is satisfied with the inference on phase 3 power given minimal success in phase 2, one would be
satisfied for any other successful phase 2 result. The confidence density depicting minimum success in
phase 2 is simply the derivative of the phase 2 power curve with respect to θ. This is depicted in Figure 7
and shows that the phase 2 decision rule from Figure 3 produces coverage probability around high values
of phase 3 power, but still assumes some risk. While the probability of success and maximum likelihood
point estimates are 78.1% and 95.9% respectively, one can also claim with 80% confidence that the power
of the phase 3 study is no less than 50% given minimal success in phase 2. Once the phase 2 study results
are available the one-sided 80% lower confidence limit (60% two-sided limits) for phase 3 power can be
provided, or conversely the level of confidence for which phase 3 power is greater than 50%, alongside the
maximum likelihood or probability of success point estimate. In our view ensuring phase 3 power is no
worse than a coin toss conditional on passing phase 2 is a good rule of thumb. If stronger inference on
phase 3 power is desired given minimal success in phase 2, one could simply increase the phase 3 sample
size. Alternatively, one could adjust the phase 2 significance level and null hypothesis, and select the phase
2 sample size based on an acceptable phase 2 minimum detectable effect (see Figure 8). See Appendix G
for additional figures.
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=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 7: Phase 3 power curve testi g H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for
θ from differentiating the phase 2 power curve testing H0 : θ ≤ −0.05 with N=90 per arm at α=0.2.
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=0.025 for phase 2 LR test against difference=-0.05 with N=225 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 8: Phase 3 power curve testing H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for θ
from differentiating the phase 2 power curve testing H0 : θ ≤ −0.05 with N=225 per arm at α=0.025.
The inference above is conditional on minimal success in phase 2 alone. One might also be interested
in performing inference on phase 3 power that incorporates the elicited confidence distribution, though
this should not weigh too heavily on decision making. Often the phase 3 probability of success calculation
is estimated through simulation while treating the elicited h(θ) as a probability distribution for θ, and is
conditioned on those Monte Carlo runs where the phase 2 success criteria is met. This subsetting amounts
to multiplying the phase 2 power curve by the elicited H(θ) and differentiating with respect to θ. This
density and the phase 3 power curve produce the conditional probability of success estimate. See curve
(iii) in Figure 9 below. When θ is considered random this density is conditional on passing phase 2, but
without conditioning on a particular value of θ, nor a particular phase 2 study result. The fixed θ inter-
pretation of the area under this density is the probability of observing a result as or more extreme than
the elicited point estimate and a result as or more extreme than the minimum detectable effect in phase
2, given a hypothesis for θ. In this inference the elicited point estimate and the phase 2 point estimate
11
are treated as separate observations. Alternatively, one could convolve the phase 2 power curve (minimum
end-of-study success cumulative confidence distribution function) with the elicited H(θ) using Equation 3
and differentiate with respect to θ to form the updated confidence density for the treatment effect. See
curve (iv) in Figure 9 below. This convolution treats the elicitation and the phase 2 study as a single
larger study. Figure 9 considers a wider elicited confidence distribution, a larger phase 2 sample size of
N=225 per arm, and a phase 2 significance level of 0.025. See Appendix H for additional figures.
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=0.025 for phase 2 LR test against difference=-0.05 with N=225 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 9: (i) Elicited confid nce density (wide). (ii) Confidence density fo θ from differentiating the phase 2
power curve testing H0 : θ ≤ −0.05 with N=225 per arm at α=0.025. (iii) Multiplication of elicited H(θ) and
phase 2 power curve, differentiated. (iv) Convolution of elicited H(θ) and phase 2 power curve, differentiated. (v)
Phase 3 power curve testing H0 : θ ≤ −0.12 with N=365 per arm at α=0.025.
This process of performing predictive inference on power can be extended to include multiple phase 2
power curves and sequentially updating the confidence distribution for the treatment effect by multiplying
or convolving the power curves as described above. For example, inference on phase 2a, phase 2b, phase 3,
and overall power conditional on passing a pilot study; inference on phase 2b, phase 3, and overall power
conditional on passing the pilot and phase 2a studies; inference on phase 3 power conditional on passing
the pilot and phase 2a and 2b studies.
If one is dissatisfied with the inference on phase 3 power after the phase 2 study results are observed,
one could consider increasing the phase 3 sample size. This will steepen the phase 3 power curve relative
to the phase 3 null hypothesis by lowering the minimum detectable effect, and improve the inference on
phase 3 success. Figure 6 could be reproduced using phase 2 inference instead of the elicitation. Of course
one could also consider conducting an additional phase 2 study and multiply or convolve the results with
the other observed phase 2 confidence distribution functions.
3.2.4 Extrapolation Between Endpoints or Control Groups Across Phases
In the examples thus far the phase 2 study used the same endpoint and treatment groups planned for phase
3. Depending on the therapeutic area and endpoint this may not be feasible. In such cases if external
or elicited data is available on both endpoints, the phase 3 endpoint can be modeled as a function of the
phase 2 endpoint. This model can then be used to transform the phase 3 treatment effect, and hence phase
12
3 power, into a function of the phase 2 treatment effect. Of course this modeling brings an additional
layer of uncertainty, and can be expressed as a confidence band around the confidence distribution. Figure
10 shows similar power curves and a confidence distribution as before, now with a 95% confidence band
around the phase 3 power curve had it been extrapolated from a different phase 3 endpoint or control
group. This extrapolation uncertainty translates into the overall power curve, and easily carries over into
Figure 11. This is a great visual to discern uncertainty around the phase 2 treatment effect and that due
to the extrapolation model. While not depicted herein, this form of extrapolation can also be used within
a single study to asses the power of multiple endpoints.
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=0.2 for phase 2 LR test against difference=-0.05 with N=? per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 10: Solid lines depict power curves for a likelihood ratio test of the difference in proportions in phase
2, phase 3, and overall. Confidence bands depict extrapolation modeling uncertainty. Dashed line depicts the
confidence density for θ based on historical data and expert opinion.
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Figure 11: Solid lines depict resulting confidence distributions for power, h(β) = dH(θ)/dβ(θ), in phase 2, phase 3,
and overall. Dotted lines depict maximum likelihood estimates of power. Confidence bands depict the extrapolation
modeling uncertainty.
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3.3 Adjustment for Multiple Comparisons
Clinical development plans almost always explore multiple endpoints and involve interim analyses, and
a natural consideration when discussing frequentist inference is the adjustment for multiple comparisons.
Even a phase 3 confirmatory setting often involves multiple studies for the explicit purpose of replicating
results, and regulatory approval can always be changed. This is to say that if one is capable of updating
previously made inference about θ, no adjustment for multiplicity is required. This perhaps reflects Fisher’s
position on meta-analysis and inductive reasoning,9,15,19 and is in some ways congruent with objective
Bayesianism, though we can not presume to know what Fisher would think if he was alive today. This
viewpoint simply emphasizes the per-comparison error rate knowing no conclusion about θ is ever final.
Fisher did of course make use of the F-test for what is known in today’s terms as controlling the family-
wise error rate in the weak sense, and used the entire context of an experiment to determine statistical
significance. Confidence distributions can certainly be used to display decision rules and study results
while adjusting for multiple comparisons if one so chooses.
4 Closing Remarks
Easily formed by inverting a hypothesis test, confidence distributions represent all possible confidence
intervals and p-values one could construct given the observed data. Confidence distributions are a re-
markable visual tool for displaying quantitative decision rules and study results, and can even be used
to display inference on power. While not demonstrated herein, confidence distributions can also be used
for conducting interim analyses. Stopping rules for early efficacy based on p-values would be displayed
similarly to Figure 3 using the data at interim, while stopping rules for futility based on inference of
end-of-study power given the data at interim would resemble Figure 9 with the confidence distribution for
the treatment effect determined, at least in part, by the interim data.
5 Data Sharing
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
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A Definition of a Confidence Interval
From Casella and Berger,10 the inference in a set estimation problem is the statement that ‘θ ∈ C,’ where
C ⊂ Θ and C = C(x) is a set determined by the value of the dataX = x observed. C ⊂ Θ is usually taken
to be an interval, and C(X) is its estimator, a random variable. The coverage probability, Pθ(θ ∈ C(X)),
is a probability statement referring to the random set C(X) since θ is an unknown fixed quantity.
B Definition of a Confidence Distribution
Definition:8 A function Hn(·) on X ×Θ→ [0, 1] is called a confidence distribution function for a parameter
θ if, R1) For each given x ∈ X , Hn(·) is a cumulative distribution function on Θ; R2) At the true parameter
value θ = θ0, Hn(θ0) ≡ Hn(x, θ0), as a function of the sample x, follows the uniform distribution U [0, 1].
Hn(·) is an asymptotic confidence distribution if the U [0, 1] requirement is true only asymptotically, and
the continuity requirement on Hn(·) is dropped. The corresponding density function, h(θ) = dH(θ)/dθ,
may also be used to depict the confidence distribution.
When the parameter space is discrete an analogous definition of a confidence distribution applies, except
the distribution provides a p-value at almost every value in the parameter space. The largest p-value(s) is
replaced with with the confidence level that creates a cumulative distribution function on the parameter
space.
For example, consider the 3x3 table below depicting the operating characteristics of a cancer screening
test with 0.85 specificity and 0.80 sensitivity. The confidence distribution shows that if the test returns an
At Risk result we can “rule out” No Cancer at the 10% level and Cancer at the 15% level and are therefore
75% confident in the alternative, which is Pre-Cancer. The 75% confidence level is nothing more than a
restatement of the p-values “ruling out” No Cancer and Cancer. Similarly, if the test returns a Positive
result we can “rule out” No Cancer at the 5% level and Pre-Cancer at the 10% level, and are therefore
85% confident in the alternative, which is Cancer.
If we have verifiable knowledge that a given subject comes from an irreducible population that has No
Cancer, Pre-Cancer, and Cancer in a 4:2:1 ratio, then the posterior depicts the long-run probability of
cancer status among randomly selected subjects, given a particular test result. This long-run probability
can be used to make inference on the cancer status of the subject at hand. In practice we may not have
verifiable knowledge about this irreducible population to which a subject belongs. One could nevertheless
use a prior, an unverifiable assumption, resulting in posterior probabilities. The normalized likelihood
can be seen as a posterior based on a 1:1:1 prior. It is more objectively viewed as an approximate
confidence distribution. The normalization smooths the operating characteristics of the screening test so
the probabilities sum to 1 over the parameter space. All four distributions below use the sampling behavior
of the screening test to form a distribution estimate of cancer status. Regardless of paradigm, multiple
tests can be performed and the results convolved to improve the inference on the true cancer status for a
given subject.
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Table 1: Cancer Screening Test
No Cancer Pre-Cancer Cancer
Negative 0.85 0.40 0.05
Operating Characteristics At Risk 0.10 0.50 0.15
Positive 0.05 0.10 0.80
Negative 0.55 0.40 0.05
Confidence Distribution At Risk 0.10 0.75 0.15
Positive 0.05 0.10 0.85
Negative 0.80 0.19 0.01
Posterior (4:2:1 Prior) At Risk 0.26 0.65 0.1
Positive 0.17 0.17 0.67
Negative 0.65 0.31 0.04
Normalized Likelihood At Risk 0.13 0.67 0.20
Positive 0.05 0.11 0.84
Negative 0.85 0.10 0.05
Plug-in Sampling Distribution At Risk 0.40 0.50 0.10
Positive 0.05 0.15 0.80
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C Constructing a Confidence Distribution
H(θ) captures the one-sided p-value for every value of θ in the parameter space, and dH(θ)/dθ is the
resulting confidence density. The confidence distribution in Figure 1 was constructed using the χ21 approx-
imation for the sampling distribution of the likelihood ratio test statistic. In Figure 12 the 2-sided p-value
testing H0 : θ = 0.75 is shaded in the left panel. Half of this is the one-sided p-value testing H0 : θ ≤ 0.75.
This is shaded above θ ≤ 0.75 in the right panel. A single χ21 reference distribution is used, and the value
of the test statistic depends on the hypothesis being tested. This approximation is particularly useful
when considering differences in parameters or other more complicated functions.
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Figure 12: Approximate χ21 null sampling distribution of the likelihood ratio test statistic for testing H0 : θ ≤ 0.75.
When performing inference on an exponential rate parameter one can note the likelihood ratio test
statistic is a monotonic function of θˆMLE = X¯, which follows a Gamma(n, θ/n) distribution. Referencing
this distribution allows the calculation of the exact likelihood ratio test p-value. In Figure 13 the left panel
shows the null sampling distribution when testing H0 : θ ≤ 0.75. The one-sided p-value in the left panel
is shaded above θ ≤ 0.75 in the right panel. The location of the null sampling distribution depends on the
hypothesis being tested.
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Figure 13: Exact null sampling distribution of θˆMLE = X¯ for testing H0 : θ ≤ 0.75.
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D Likelihood Ratio Test for Difference in Proportions
Let Xcrtl ∼ Bin(nctrl, pctrl), Xactive ∼ Bin(nactive, pactive), θ = pactive − pctrl, and pctrl, θ ∈ Θ.
L(pctrl, θ) ∝ (pctrl)
xctrl(1 − pctrl)
nctrl−xctrl(pctrl + θ)
xactive (1− pctrl − θ)
nactive−xactive
∂ℓ(pctrl, θ)
∂pctrl
=
xctrl
pctrl
−
nctrl − xctrl
1− pctrl
+
xactive
pctrl + θ
−
nactive − xactive
1− pctrl − θ
∂ℓ(pctrl, θ)
∂θ
=
xactive
pctrl + θ
−
nactive − xactive
1− pctrl − θ
sup
pctrl,θ∈Θ
L(pctrl, θ) = L(pˆctrl, θˆ) yields pˆctrl = xctrl/nctrl and θˆ = xactive/nactive − xctrl/nctrl.
Under H0 : θ = θ0, sup
pctrl,θ∈Θ0
L(pctrl, θ) = L(pˆ
ctrl
0 , θ0) where
∂ℓ(pctrl, θ0)
∂pctrl
set
= 0
=⇒ pˆctrl0,1 =
xctrl +
xactivepˆctrl
pˆctrl+θ0
(1− pˆctrl) +
xactive(1−pˆctrl)
1−pˆctrl−θ0
pˆctrl
nctrl +
nactive(1−pˆctrl)
1−pˆctrl−θ0
pˆctrl0,k+1 =
xctrl +
xactivepˆ
ctrl
0,k
pˆctrl
0,k
+θ0
(1− pˆctrl0,k ) +
xactive(1−pˆ
ctrl
0,k )
1−pˆctrl
0,k
−θ0
pˆctrl0,k
nctrl +
nactive(1−pˆctrl0,k )
1−pˆctrl
0,k
−θ0
, k = 1, 2, ...,K
for K sufficiently large to reach convergence. The likelihood ratio test statistic,
−2logλ(X) = −2log
(
L(pˆctrl0 , θ0)
L(pˆctrl, θˆ)
)
,
follows an asymptotic chi-squared distribution with 1 degree of freedom, and significance at level α is
achieved if −2logλ(x) > χ21,α, the 1 − α percentile. The corresponding two-sided, equal-tailed (1 − α)%
confidence interval is given by {θ : −2logλ(x) ≤ χ21,α}.
E Determining Effective Sample Size
If a literature review and elicitation provides an estimated sampling distribution for the response proportion
on control and the difference over control, the first two moments of these distributions can be used to
determine the effective sample size for the active arm.
Vˆar(pˆactive − pˆctrl) =
σˆ2active
n
+
σˆ2ctrl
m
Vˆar(pˆactive − pˆctrl) =
pˆactive(1− pˆactive)
n
+
pˆctrl(1 − pˆctrl)
m
Vˆar(pˆactive − pˆctrl)−
pˆctrl(1− pˆctrl)
m
=
pˆactive(1− pˆactive)
n
n =
pˆactive(1− pˆactive)
Vˆar(pˆactive − pˆctrl)−
pˆctrl(1−pˆctrl)
m
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Confidence DensityPhase 2 and 3 Power
Phase 3 PowerPhase 2 Power
=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 14: Phase 2 power curve testing H0 : θ ≤ −0.05 with N=90 per arm at α=0.2. Phase 3 power curve testing
H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for θ based on historical data and expert
opinion.
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Figure 15: Solid lines depict resulting confidence distributions for power, h(β) = dH(θ)/dβ(θ), in phase 2, phase
3, and overall. Dotted lines depict maximum likelihood estimates of power.
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footFigure 16: Estimated phase 3 power testingH0 : θ ≤ −0.12 at α=0.025 at various sample sizes with 80% confidence
limits based on the elicitation (wide).
21
G Additional Figures
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=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 17: Phase 3 power curve test g H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for
θ from differentiating the phase 2 power curve testing H0 : θ ≤ −0.05 with N=90 per arm at α=0.2.
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Figure 18: Solid line depicts resulting confidence distribution for phase 3 power conditional on minimally passing
phase 2. Dotted line depicts maximum likelihood estimate of phase 3 power, 0.959. Probability of success estimate
of power equals 0.781.
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=0.025 for phase 2 LR test against difference=-0.05 with N=225 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 19: Phase 3 power curve test g H0 : θ ≤ −0.12 with N=365 per arm at α=0.025. Confidence density for
θ from differentiating the phase 2 power curve testing H0 : θ ≤ −0.05 with N=225 per arm at α=0.025.
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Figure 20: Solid line depicts resulting confidence distribution for phase 3 power conditional on minimally passing
phase 2. Dotted line depicts maximum likelihood estimate of phase 3 power, 0.994. Probability of success estimate
of power equals 0.938.
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(iv) Convolution(iii) Multiplication
(ii) Minimum Phase 2 Success(i) Elicited Confidence Density
=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 21: (i) Elicit d confid nce density (narrow). (ii) Confidence density for θ from differentiating the phase 2
power curve testing H0 : θ ≤ −0.05 with N=90 per arm at α=0.2. (iii) Multiplication of elicited H(θ) and phase 2
power curve, differentiated. (iv) Convolution of elicited H(θ) and phase 2 power curve, differentiated. (v) Phase 3
power curve testing H0 : θ ≤ −0.12 with N=365 per arm at α=0.025.
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(v) Phase 3 Power
(iv) Convolution(iii) Multiplication
(ii) Minimum Phase 2 Success(i) Elicited Confidence Density
=0.025 for phase 2 LR test against difference=-0.05 with N=225 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 2: (i) Elicit d confidence density (narrow). (ii) Confidence density for θ from differentiating the phase
2 power curve testing H0 : θ ≤ −0.05 with N=225 per arm at α=0.025. (iii) Multiplication of elicited H(θ) and
phase 2 power curve, differentiated. (iv) Convolution of elicited H(θ) and phase 2 power curve, differentiated. (v)
Phase 3 power curve testing H0 : θ ≤ −0.12 with N=365 per arm at α=0.025.
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(v) Phase 3 Power
(iv) Convolution(iii) Multiplication
(ii) Minimum Phase 2 Success(i) Elicited Confidence Density
=0.2 for phase 2 LR test against difference=-0.05 with N=90 per arm.
=0.025 for phase 3 LR test against difference=-0.12 with N=365 per arm.Figure 3: (i) Elicited confidence density (wid ). (ii) Confidence density fo θ from differentiating the phase 2
power curve testing H0 : θ ≤ −0.05 with N=90 per arm at α=0.2. (iii) Multiplication of elicited H(θ) and phase 2
power curve, differentiated. (iv) Convolution of elicited H(θ) and phase 2 power curve, differentiated. (v) Phase 3
power curve testing H0 : θ ≤ −0.12 with N=365 per arm at α=0.025.
I SAS Code
%l e t d d i f f =0.001;
data binomial ;
∗ d i f f i s the theta axi s , the true d i f f e r e n c e in propor t i ons ;
do d i f f =−0.2 to 0 . 25 by &dd i f f . ;
∗ E l i c i t a t i o n ;
i n t c t r l =0.43;
d i f f h a t =−0.02;
n c t r l =1200;
n ac t i v e =350;
y c t r l=i n t c t r l ∗ n c t r l ;
y a c t i v e =( i n t c t r l+d i f f h a t )∗ n ac t i v e ;
∗Wald CD;
/∗
p ac t i v e=y ac t i v e / n ac t i v e ;
se=sq r t ( p ac t i v e ∗(1− p ac t i v e )/ n ac t i v e + i n t c t r l ∗(1− i n t c t r l )/ n c t r l ) ;
H=1−cd f ( ’ normal ’ , ( d i f f h a t−d i f f )/ ( se ) ) ;
∗/
∗Like l i hood Ratio Test ;
i n t c t r l n u l l =( y c t r l +(y ac t i v e /( i n t c t r l+d i f f ) )∗ i n t c t r l −(( y ac t i v e /( i n t c t r l+d i f f ) )
∗ i n t c t r l )∗ i n t c t r l +(y ac t i v e ∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) )∗ i n t c t r l )
/( n c t r l +(n ac t i v e ∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) ) ) ;
do i=1 to 100 ;
i n t c t r l n u l l =( y c t r l +(y ac t i v e /( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l −(( y ac t i v e
25
/( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l )∗ i n t c t r l n u l l +(y ac t i v e ∗(1− i n t c t r l n u l l )
/(1− i n t c t r l n u l l −d i f f ) )∗ i n t c t r l n u l l )/ ( n c t r l +(n ac t i v e ∗(1− i n t c t r l n u l l )
/(1− i n t c t r l n u l l −d i f f ) ) ) ;
end ;
lambda=(( i n t c t r l n u l l / i n t c t r l )∗∗ y c t r l )∗ ( ( (1− i n t c t r l n u l l )/ (1− i n t c t r l ) )
∗∗( n c t r l−y c t r l ) )∗ ( ( ( i n t c t r l n u l l+d i f f )/ ( i n t c t r l+d i f f h a t ) )∗∗ y ac t i v e )
∗(((1− i n t c t r l n u l l −d i f f )/ (1− i n t c t r l −d i f f h a t ) )∗∗ ( n act i ve−y ac t i v e ) ) ;
loglambda=log ( lambda ) ;
minus2loglambda=−2∗loglambda ;
i f d i f f gt d i f f h a t then do ;
H=(1+cdf ( ’ chi square ’ ,−2∗ loglambda , 1 ) ) / 2 ;
end ;
i f d i f f l e d i f f h a t then do ;
H=(1−cd f ( ’ chi square ’ ,−2∗ loglambda , 1 ) ) / 2 ;
end ;
dHddi f f=(H−l ag (H) )/ ( d i f f −l ag ( d i f f ) ) ;
∗Phase 2 ;
n ac t i v e pha s e2 =90; c a l l symput ( ’ n act i ve phase2 ’ , tr im ( l e f t ( n ac t i v e pha s e2 ) ) ) ;
n c t r l pha s e2 =90; c a l l symput ( ’ n c t r l pha s e2 ’ , tr im ( l e f t ( n c t r l pha s e2 ) ) ) ;
∗ nu l l hypothes i s ;
lower margin2=−0.05; c a l l symput ( ’ lower margin phase2 ’ , s t r i p ( lower margin2 ) ) ;
a lpha phase2 =0.20; c a l l symput ( ’ a lpha phase2 ’ , s t r i p ( alpha phase2 ) ) ;
∗minimum dete c tab l e e f f e c t ;
l ower cv2=lower margin2 +0.064; c a l l symput ( ’ phase2 mle succes s ’ , l ower cv2 ) ;
y c t r l p h a s e 2=i n t c t r l ∗( n c t r l pha s e2 ) ;
y a c t i v e pha s e2=( i n t c t r l+lower cv2 )∗ n ac t i v e pha s e2 ;
∗Wald ;
/∗ p ac t i v e pha s e2=y ac t i v e pha s e2 / n ac t i v e pha s e2 ;
p c t r l pha s e2=y c t r l p h a s e 2 / n c t r l pha s e2 ;
s e phase2=sq r t ( p ac t i v e pha s e2 ∗(1− p ac t i v e pha s e2 )/ n ac t i v e pha s e2 + p c t r l pha s e2
∗(1− p c t r l pha s e2 )/ n c t r l pha s e2 ) ;
phase2 power=1−cd f ( ’ normal ’ , ( p act i ve phase2−p c t r l pha s e2−d i f f )/ se phase2 , 0 , 1 ) ; ∗ /
∗Like l i hood Ratio Test ;
i n t c t r l n u l l =(y c t r l p h a s e 2+(y ac t i v e pha s e2 /( i n t c t r l+d i f f ) )∗ i n t c t r l
−(( y ac t i v e pha s e2 /( i n t c t r l+d i f f ) )∗ i n t c t r l )∗ i n t c t r l +(y ac t i v e pha s e2
∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) )∗ i n t c t r l )/ ( n c t r l pha s e2 +(n ac t i v e pha s e2
∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) ) ) ;
do i=1 to 100 ;
i n t c t r l n u l l =(y c t r l p h a s e 2+(y ac t i v e pha s e2 /( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l
−(( y ac t i v e pha s e2 /( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l )∗ i n t c t r l n u l l
+(y ac t i v e pha s e2 ∗(1− i n t c t r l n u l l )/(1− i n t c t r l n u l l −d i f f ) )∗ i n t c t r l n u l l )
/( n c t r l pha s e2 +(n ac t i v e pha s e2 ∗(1− i n t c t r l n u l l )/(1− i n t c t r l n u l l −d i f f ) ) ) ;
end ;
l i k e l i h o od pha s e 2=( i n t c t r l n u l l ∗∗ y c t r l p h a s e 2 )∗(1− i n t c t r l n u l l )∗∗ ( n c t r l pha s e2
−y c t r l p h a s e 2 )∗ ( ( i n t c t r l n u l l+d i f f )∗∗ ( y ac t i v e pha s e2 ) )
∗((1− i n t c t r l n u l l −d i f f )∗∗ ( n act i ve phase2−y ac t i v e pha s e2 ) ) ;
l i k e l i h o od 1 pha s e 2=( i n t c t r l ∗∗ y c t r l p h a s e 2 )∗(1− i n t c t r l )∗∗ ( n c t r l pha s e2
−y c t r l p h a s e 2 )∗ ( ( i n t c t r l+lower cv2 )∗∗ ( y ac t i v e pha s e2 ))∗((1− i n t c t r l
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−l ower cv2 )∗∗ ( n act i ve phase2−y ac t i v e pha s e2 ) ) ;
lambda phase2=( l i k e l i h o od pha s e 2 )/( l i k e l i h o od 1 pha s e 2 ) ;
loglambda phase2=log ( lambda phase2 ) ;
minus2loglambda phase2=−2∗ loglambda phase2 ;
i f d i f f l t l ower cv2 then do ;
phase2 power=(1− cd f ( ’ chi square ’ ,−2∗ loglambda phase2 , 1 ) ) / 2 ;
end ;
e l s e i f d i f f ge l ower cv2 then do ;
phase2 power=(1+cdf ( ’ chi square ’ ,−2∗ loglambda phase2 , 1 ) ) / 2 ;
end ;
∗CD f o r d e f i n i t i o n o f s u c c e s s ;
H phase2 succes s=phase2 power ;
dH phas e2 succ e s s dd i f f=(H phase2 success−l ag ( H phase2 succes s ) ) / ( d i f f−l ag ( d i f f ) ) ;
∗Phase 3 ;
n c t r l pha s e3 =365; c a l l symput ( ’ n c t r l pha s e3 ’ , tr im ( l e f t ( n c t r l pha s e3 ) ) ) ;
n a c t i v e pha s e3 =365; c a l l symput ( ’ n act i ve phase3 ’ , tr im ( l e f t ( n ac t i v e pha s e3 ) ) ) ;
∗ nu l l hypothes i s ;
lower margin3=−0.12; c a l l symput ( ’ lower margin phase3 ’ , s t r i p ( lower margin3 ) ) ;
a lpha phase3 =0.025; c a l l symput ( ’ a lpha phase3 ’ , s t r i p ( alpha phase3 ) ) ;
∗minimum dete c tab l e e f f e c t ;
l ower cv3=lower margin3 +0.071;
y c t r l p h a s e 3=i n t c t r l ∗ n c t r l pha s e3 ;
y ac t i v e pha s e3=( i n t c t r l+lower cv3 )∗ n ac t i v e pha s e3 ;
∗Wald ;
/∗ p ac t i v e pha s e3=y ac t i v e pha s e3 / n ac t i v e pha s e3 ;
p c t r l pha s e3=y c t r l p h a s e 3 / n c t r l pha s e3 ;
s e phase3=sq r t ( p ac t i v e pha s e3 ∗(1− p ac t i v e pha s e3 )/ n ac t i v e pha s e3
+ p c t r l pha s e3 ∗(1− p c t r l pha s e3 )/ n c t r l pha s e3 ) ;
phase3 power1=1−cd f ( ’ normal ’ , ( p act i ve phase3−p c t r l pha s e3−d i f f )/ se phase3 , 0 , 1 ) ;∗ /
∗Like l i hood Ratio Test ;
i n t c t r l n u l l =(y c t r l p h a s e 3+(y ac t i v e pha s e3 /( i n t c t r l+d i f f ) )∗ i n t c t r l
−(( y ac t i v e pha s e3 /( i n t c t r l+d i f f ) )∗ i n t c t r l )∗ i n t c t r l +(y ac t i v e pha s e3
∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) )∗ i n t c t r l )/ ( n c t r l pha s e3 +(n ac t i v e pha s e3
∗(1− i n t c t r l )/(1− i n t c t r l −d i f f ) ) ) ;
do i=1 to 100 ;
i n t c t r l n u l l =(y c t r l p h a s e 3+(y ac t i v e pha s e3 /( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l
−(( y ac t i v e pha s e3 /( i n t c t r l n u l l+d i f f ) )∗ i n t c t r l n u l l )∗ i n t c t r l n u l l
+(y ac t i v e pha s e3 ∗(1− i n t c t r l n u l l )/(1− i n t c t r l n u l l −d i f f ) )∗ i n t c t r l n u l l )
/( n c t r l pha s e3 +(n ac t i v e pha s e3 ∗(1− i n t c t r l n u l l )/(1− i n t c t r l n u l l −d i f f ) ) ) ;
end ;
l i k e l i h o od pha s e 3=( i n t c t r l n u l l ∗∗ y c t r l p h a s e 3 )∗(1− i n t c t r l n u l l )∗∗ ( n c t r l pha s e3
−y c t r l p h a s e 3 )∗ ( ( i n t c t r l n u l l+d i f f )∗∗ ( y ac t i v e pha s e3 ))∗((1− i n t c t r l n u l l
−d i f f )∗∗ ( n act i ve phase3−y ac t i v e pha s e3 ) ) ;
l i k e l i h o od 1 pha s e 3=( i n t c t r l ∗∗ y c t r l p h a s e 3 )∗(1− i n t c t r l )∗∗ ( n c t r l pha s e3
−y c t r l p h a s e 3 )∗ ( ( i n t c t r l+lower cv3 )∗∗ ( y ac t i v e pha s e3 ))∗((1− i n t c t r l
−l ower cv3 )∗∗ ( n act i ve phase3−y ac t i v e pha s e3 ) ) ;
lambda phase3=( l i k e l i h o od pha s e 3 )/( l i k e l i h o od 1 pha s e 3 ) ;
loglambda phase3=log ( lambda phase3 ) ;
minus2loglambda phase3=−2∗ loglambda phase3 ;
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i f d i f f l t l ower cv3 then do ;
phase3 power=(1− cd f ( ’ chi square ’ ,−2∗ loglambda phase3 , 1 ) ) / 2 ;
end ;
e l s e i f d i f f ge l ower cv3 then do ;
phase3 power=(1+cdf ( ’ chi square ’ ,−2∗ loglambda phase3 , 1 ) ) / 2 ;
end ;
i f phase3 power=0 then phase3 power =. ;
∗CD f o r d e f i n i t i o n o f s u c c e s s ;
H phase3 succes s=phase3 power ;
dH phas e3 succ e s s dd i f f=(H phase3 success−l ag ( H phase3 succes s ) ) / ( d i f f−l ag ( d i f f ) ) ;
∗CDs f o r Power . Der ivat i ve o f H wrt power ;
phase2and3 power=phase3 power∗phase2 power ;
dH dpower=(H−l ag (H) )/ ( phase3 power−l ag ( phase3 power ) ) ;
i f dH dpower =0 then dH dpower =. ;
i f 0 gt phase3 power gt 1 then dH dpower=. ;
dH dphase2power=(H−l ag (H) )/ ( phase2 power−l ag ( phase2 power ) ) ;
i f dH dphase2power =0 then dH dphase2power =. ;
i f 0 gt phase2 power gt 1 then dH dphase2power =. ;
dH dphase23power=(H−l ag (H) )/ ( phase2and3 power−l ag ( phase2and3 power ) ) ;
i f 0 gt phase2and3 power gt 1 then dH dphase23power =. ;
dH phase2 dphase3=(H phase2 success−l ag ( H phase2 succes s ) ) / ( phase3 power
−l ag ( phase3 power ) ) ;
∗Addi t i ona l phase 2 i n f e r e n c e ;
H mult ip ly=H∗H phase2 succes s ;
dH mu l t i p l y dd i f f=(H multiply−l ag ( H mult ip ly ) ) / ( d i f f −l ag ( d i f f ) ) ;
e l i c i t e d v a r =( d i f f h a t+i n t c t r l )∗(1− d i f f h a t − i n t c t r l )/ n ac t i v e+( i n t c t r l )
∗(1− i n t c t r l )/ n c t r l ;
phase2 var=( l ower cv2+i n t c t r l )∗(1− l ower cv2− i n t c t r l )/ n ac t i v e pha s e2
+i n t c t r l ∗(1− i n t c t r l )/ n c t r l pha s e2 ;
phase3 var=( l ower cv3+i n t c t r l )∗(1− l ower cv3− i n t c t r l )/ n ac t i v e pha s e3
+i n t c t r l ∗(1− i n t c t r l )/ n c t r l pha s e3 ;
H convolve=cdf ( ’ normal ’ , ( quan t i l e ( ’ normal ’ ,H, 0 , 1 )/ s q r t ( e l i c i t e d v a r )
+quant i l e ( ’ normal ’ , H phase2 success , 0 , 1 )/ s q r t ( phase2 var ) )
/ s q r t (1/( e l i c i t e d v a r ) + 1/( phase2 var ) ) , 0 , 1 ) ;
dH convo lve dd i f f=(H convolve−l ag ( H convolve ) )/ ( d i f f −l ag ( d i f f ) ) ;
∗Weights f o r PoS c a l c u l a t i o n s ;
weight=H−l ag (H) ;
weight phase3cond2=H phase2 success−l ag ( H phase2 succes s ) ;
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∗Reference l i n e s and shaded r eg i on s in f i g u r e s ;
i f d i f f l e lower margin2 then r e f 1=alpha phase2 ; e l s e r e f 1 =. ;
i f d i f f l e lower margin3 then r e f 2=alpha phase3 ; e l s e r e f 2 =. ;
i f phase2 power l e alpha phase2 then r e f 3=lower margin2 ; e l s e r e f 3 =. ;
i f phase3 power l e alpha phase3 then r e f 4=lower margin3 ; e l s e r e f 4 =. ;
i f d i f f l e lower margin2 then r e f 5 =0.5; e l s e r e f 5 =. ;
i f phase3 power l e 0 . 5 then r e f 6=lower margin2 ; e l s e r e f 6 =. ;
i f 0 . 49 l e phase2 power l e 0 . 51 then do ; c a l l symput ( ’ t a i l 2 ’ ,H) ; end ;
i f 0 . 49 l e phase3 power l e 0 . 51 then do ; c a l l symput ( ’ t a i l 3 ’ ,H) ; end ;
i f 0 . 49 l e phase2and3 power l e 0 . 51 then do ; c a l l symput ( ’ t a i l 2 3 ’ ,H) ; end ;
i f H phase2 succes s l e a lpha phase2 then area=dH phas e2 succ e s s dd i f f ;
e l s e area =. ;
i f H phase2 succes s l e a lpha phase2 then area2=dH phase2 dphase3 ;
e l s e area2 =. ;
output ;
end ;
run ;
∗PoS Ca l cu l a t i on s ;
proc means data=binomial mean nopr int ;
weight weight ;
var phase2 power phase3 power phase2and3 power ;
output out=mean power ( where=( s t a t =’MEAN’ ) ) ;
run ;
proc means data=binomial mean nopr int ;
weight weight phase3cond2 ;
var phase3 power ;
output out=mean phase3cond2 power mean=phase3cond2 power ;
run ;
data mean power ;
s e t mean power ;
c a l l symput ( ’ mean phase2 power ’ , s t r i p ( round ( phase2 power , 0 . 0 0 1 ) ) ) ;
c a l l symput ( ’ mean phase3 power ’ , s t r i p ( round ( phase3 power , 0 . 0 0 1 ) ) ) ;
c a l l symput ( ’ mean phase23 power ’ , s t r i p ( round ( phase2and3 power , 0 . 0 0 1 ) ) ) ;
run ;
data mean phase3cond2 power ;
s e t mean phase3cond2 power ;
c a l l symput ( ’ mean phase3cond2 power ’ , s t r i p ( round ( phase3cond2 power , 0 . 0 0 1 ) ) ) ;
run ;
∗MLEs;
proc s q l nopr int ;
s e l e c t d i f f h a t
i n to : d i f f h a t
from binomial ;
qu i t ;
proc means data=binomial nopr int ;
where &d i f f h a t .−&dd i f f . l e d i f f l e &d i f f h a t .+&dd i f f . ;
var phase2 power phase3 power phase2and3 power ;
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output out=mles power ( where=( s t a t =’MIN’ ) ) ;
run ;
proc means data=binomial nopr int ;
where 0.5−&dd i f f . l e H phase2 succes s l e 0.5+&dd i f f . ;
var phase3 power ;
output out=mle phase3cond2 power ( where=( s t a t =’MIN’ ) ) ;
run ;
data mles power ;
s e t mles power ;
c a l l symput ( ’ phase2 power mle ’ , s t r i p ( round ( phase2 power , 0 . 0 0 1 ) ) ) ;
c a l l symput ( ’ phase3 power mle ’ , s t r i p ( round ( phase3 power , 0 . 0 0 1 ) ) ) ;
c a l l symput ( ’ phase23 power mle ’ , s t r i p ( round ( phase2and3 power , 0 . 0 0 1 ) ) ) ;
run ;
data mle phase3cond2 power ;
s e t mle phase3cond2 power ;
c a l l symput ( ’ phase3cond2 power mle ’ , s t r i p ( round ( phase3 power , 0 . 0 0 1 ) ) ) ;
run ;
∗Prepare f o r p l o t s ;
data b inomia l s tack ;
s e t binomial ( i n=a ) binomial ( i n=b ) ;
i f a then do ;
phase=2;
dH succ e s s dd i f f=dH phas e2 succ e s s dd i f f ;
mle=lower cv2 ;
lower margin=lower margin2 ;
end ;
i f b then do ;
phase=3;
dH succ e s s dd i f f=dH phas e3 succ e s s dd i f f ;
mle=lower cv3 ;
lower margin=lower margin3 ;
end ;
run ;
∗Check type I e r r o r r a t e s ;
proc s q l nopr int ;
s e l e c t max( phase2 power )
i n to : cp phase2
from binomia l s tack
where lower margin2−&dd i f f . < d i f f < l ower margin2 + &dd i f f . and phase =2;
s e l e c t max( phase3 power )
i n to : cp phase3
from binomia l s tack
where lower margin3−&dd i f f . < d i f f < l ower margin3 + &dd i f f . and phase =3;
qu i t ;
%put &cp phase2 . &cp phase3 . ;
∗Plots ;
proc format ;
value phase 2=’Phase 2 Success ’
3=’Phase 3 Success ’
;
run ;
30
ods escapechar = ’ˆ ’ ;
opt i ons nodate nonumber ;
ods graph i cs / border=no he i ght=3in width=6.0 in ;
proc sgpane l data=binomia l s tack noautolegend ;
panelby phase / novarname ;
format phase phase . ;
r e f l i n e lower margin / ax i s=x l i n e a t t r s =(pattern=dot ) ;
s e r i e s x=d i f f y=dH succe s s dd i f f / group=phase l i n e a t t r s =( th i ckne s s =1);
rowaxis l a b e l=”Conf idence Density ” ;
c o l a x i s l a b e l=”True D i f f e r enc e in Propor t i ons ” ;
f ootnote1 j=l e f t ”ˆ{ unicode alpha}=&alpha phase2 . f o r phase 2 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase2 . with N=&n ct r l pha s e2 . per arm . ” ;
f ootnote2 j=l e f t ”ˆ{ unicode alpha}=&alpha phase3 . f o r phase 3 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase3 . with N=&n ct r l pha s e3 . per arm . ” ;
run ;
opt i ons nodate nonumber ;
ods graph i cs / border=no he i ght=3in width=6.0 in ;
ods es capechar=”ˆ”;
proc s gp l o t data=binomial noautolegend ;
r e f l i n e d i f f h a t / ax i s=x l i n e a t t r s =( th i ckne s s =0.5) ;
s e r i e s x=d i f f y=phase2 power / l i n e a t t r s =( th i ckne s s =1) name=”phase2 power ” ;
s e r i e s x=d i f f y=phase3 power / l i n e a t t r s =( th i ckne s s=2 co l o r=cxD05B5B )
name=”phase3 power ” ;
s e r i e s x=d i f f y=phase2and3 power / l i n e a t t r s =( th i ckne s s=4 co l o r=cx66A5A0)
name=”phase2and3 power ” ;
s e r i e s x=d i f f y=dHddi f f / l i n e a t t r s =( th i ckne s s=2 pattern=dash co l o r=black ) y2ax i s
name=”CD” ;
keylegend ”phase2 power ” ”phase3 power ” ”phase2and3 power” ”CD” ;
s e r i e s x=d i f f y=r e f 1 / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
s e r i e s x=d i f f y=r e f 2 / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
s e r i e s x=r e f 3 y=phase2 power / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
s e r i e s x=r e f 4 y=phase3 power / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
y2ax i s va lues =(0 to 24 by 4 ) ;
f ootnote1 j=l e f t ”ˆ{ unicode alpha}=&alpha phase2 . f o r phase 2 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase2 . with N=&n ct r l pha s e2 . per arm . ” ;
f ootnote2 j=l e f t ”ˆ{ unicode alpha}=&alpha phase3 . f o r phase 3 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase3 . with N=&n ct r l pha s e3 . per arm . ” ;
xax i s l a b e l=”True D i f f e r enc e in Propor t i ons ” ;
yax i s l a b e l=”Power ” ;
l a b e l phase2 power=”Phase 2 Power” phase3 power=”Phase 3 Power”
phase2and3 power=”Phase 2 and 3 Power” dHddi f f=”Conf idence Density ” ;
run ;
ods graph i cs / border=no he i ght =3.5 in width=6.0 in ;
proc s gp l o t data=binomial ;
s e r i e s x=phase2 power y=dH dphase2power / l i n e a t t r s =( th i ckne s s =1) name=”phase2 power ” ;
s e r i e s x=phase3 power y=dH dpower / l i n e a t t r s =( th i ckne s s=2 co l o r=cxD05B5B )
name=”phase3 power ” ;
s e r i e s x=phase2and3 power y=dH dphase23power / l i n e a t t r s =( th i ckne s s=4 co l o r=cx66A5A0)
name=”phase23 power ” ;
r e f l i n e &phase2 power mle . / ax i s=x l i n e a t t r s =( co l o r=blue pattern=dot )
l e g end l abe l =”Phase 2 Power mle” name=”Phase 2 PoS (Power mle ) ” ;
r e f l i n e &phase3 power mle . / ax i s=x l i n e a t t r s =( co l o r=cxD05B5B pattern=dot th i ckne s s =2)
l e g end l abe l =”Phase 3 Power mle” name=”Phase 3 PoS (Power mle ) ” ;
r e f l i n e &phase23 power mle . / ax i s=x l i n e a t t r s =( co l o r=cx66A5A0 pattern=dot th i ckne s s =4)
l e g end l abe l =”Phase 2 and 3 Power mle” name=”Phase 2 and 3 PoS (Power mle ) ” ;
f ootnote1 j=l e f t ”Phase 2 Power : mle=&phase2 power mle . , pos=&mean phase2 power . ” ;
f ootnote2 j=l e f t ”Phase 3 Power : mle=&phase3 power mle . , pos=&mean phase3 power . ” ;
f ootnote3 j=l e f t ”Phase 2 and 3 Power : mle=&phase23 power mle . ,
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pos=&mean phase23 power . ” ;
xax i s l a b e l=”Power ” ;
yax i s l a b e l=”Conf idence Density ” min=0 max=6;
l a b e l dH dphase2power=”Phase 2 CD” dH dpower=”Phase 3 CD”
dH dphase23power=”Phase 2 and 3 CD” ;
keylegend ”phase2 power ” ”phase3 power ” ”phase23 power ” ”Phase 2 PoS (Power mle )”
”Phase 3 PoS (Power mle )” ”Phase 2 and 3 PoS (Power mle )” ;
run ;
f oo tno t e ;
opt i ons nodate nonumber ;
ods graph i cs / border=no he i ght=3in width=6.0 in ;
ods es capechar=”ˆ”;
proc s gp l o t data=binomial noautolegend ;
band x=d i f f upper=area lower=0 / f i l l a t t r s =( co l o r=l i g h t g r e y ) y2ax i s ;
r e f l i n e l ower cv2 / ax i s=x l i n e a t t r s =( th i ckne s s =0.5) ;
s e r i e s x=d i f f y=dH phas e2 succ e s s dd i f f / l i n e a t t r s =( th i ckne s s=1 pattern=s o l i d )
y2ax i s name=”CD” l eg end l abe l =”Minimum Phase 2 Succes s ” ;
s e r i e s x=d i f f y=phase3 power / l i n e a t t r s =( th i ckne s s=2 co l o r=cxD05B5B )
name=”phase3 power ” ;
keylegend ”phase2 power ” ”phase3 power ” ”phase2and3 power” ”CD” ;
s e r i e s x=d i f f y=r e f 5 / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
s e r i e s x=r e f 6 y=phase3 power / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
y2ax i s va lues =(0 to 24 by 4 ) ;
f ootnote1 j=l e f t ”ˆ{ unicode alpha}=&alpha phase2 . f o r phase 2 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase2 . with N=&n ct r l pha s e2 . per arm . ” ;
f ootnote2 j=l e f t ”ˆ{ unicode alpha}=&alpha phase3 . f o r phase 3 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase3 . with N=&n ct r l pha s e3 . per arm . ” ;
xax i s l a b e l=”True D i f f e r enc e in Propor t i ons ” ;
yax i s l a b e l=”Power ” ;
l a b e l phase3 power=”Phase 3 Power”
dH phas e2 succ e s s dd i f f=”Conf idence Density ” ;
run ;
f oo tno t e ;
ods graph i cs / border=no he i ght =3.5 in width=6.0 in ;
proc s gp l o t data=binomial ;
band x=phase3 power upper=area2 lower=0 / f i l l a t t r s =( co l o r=l i g h t g r e y ) ;
s e r i e s x=phase3 power y=dH phase2 dphase3 / l i n e a t t r s =( th i ckne s s=2 co l o r=cxD05B5B )
name=”phase3 power ” ;
r e f l i n e &phase3cond2 power mle . / ax i s=x l i n e a t t r s =( co l o r=cxD05B5B pattern=dot
th i ckne s s =2) l e g end l abe l =”Phase 3 Power mle” name=”Phase 3 Power mle ” ;
f ootnote1 j=l e f t ”Phase 3 Power : mle=%sys func ( s t r i p (&phase3cond2 power mle . ) ) ,
pos=&mean phase3cond2 power . ” ;
xax i s l a b e l=”Power ” ;
yax i s l a b e l=”Conf idence Density ” min=0 max=6;
l a b e l dH phase2 dphase3=”Phase 3 CD” ;
keylegend ”phase3 power ” ”Phase 3 Power mle” ;
run ;
f oo tno t e ;
opt i ons nodate nonumber ;
ods graph i cs / border=no he i ght =3.5 in width=6.0 in ;
proc s gp l o t data=binomial ;
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s e r i e s x=d i f f y=dH phas e2 succ e s s dd i f f / l i n e a t t r s =(pattern=s o l i d ) name=”phase 2”
l eg end l abe l =”( i i ) Minimum Phase 2 Succes s ” y2ax i s ;
s e r i e s x=d i f f y=phase3 power / l i n e a t t r s =( th i ckne s s=2 co l o r=cxD05B5B )
name=”phase3 power ” l e g end l abe l =”(v ) Phase 3 Power ” ;
s e r i e s x=d i f f y=dH mul t i p l y dd i f f / l i n e a t t r s =(pattern=8) name=”mul t ip ly”
l e g end l abe l =”( i i i ) Mu l t i p l i c a t i on ” y2ax i s ;
s e r i e s x=d i f f y=dH convo lve dd i f f / l i n e a t t r s =(pattern=3) name=”convo lut i on ”
l eg end l abe l =”( iv ) Convolution ” y2ax i s ;
s e r i e s x=d i f f y=dHddi f f / l i n e a t t r s =( co l o r=black th i ckne s s=2 pattern=dash )
name=” e l i c i t e d ” l eg end l abe l =”( i ) E l i c i t e d Conf idence Density ” y2ax i s ;
xax i s l a b e l=”True D i f f e r enc e in Propor t i ons ” ;
yax i s l a b e l=”Power ” ;
y2ax i s va lues =(0 to 24 by 4) l a b e l=”Conf idence Density ” ;
keylegend ” e l i c i t e d ” ”phase 2” ”mul t ip ly” ” convo lut i on ” ”phase3 power ” ;
s e r i e s x=d i f f y=r e f 2 / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
s e r i e s x=r e f 4 y=phase3 power / l i n e a t t r s =( co l o r=grey pattern=dot ) ;
r e f l i n e d i f f h a t / ax i s=x l i n e a t t r s =( th i ckne s s =0.5) ;
f ootnote1 j=l e f t ”ˆ{ unicode alpha}=&alpha phase2 . f o r phase 2 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase2 . with N=&n ct r l pha s e2 . per arm . ” ;
f ootnote2 j=l e f t ”ˆ{ unicode alpha}=&alpha phase3 . f o r phase 3 LR t e s t aga i n s t d i f f e r e n c e
<= &lower margin phase3 . with N=&n ct r l pha s e3 . per arm . ” ;
run ;
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